Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1241P - Effects of different brain radiotherapy strategies based on lung-molGPA stratification on the prognosis of patients with brain metastases of EGFR-mutant lung adenocarcinoma

Date

16 Sep 2021

Session

ePoster Display

Presenters

Guangchuan Deng

Citation

Annals of Oncology (2021) 32 (suppl_5): S949-S1039. 10.1016/annonc/annonc729

Authors

G. Deng

Author affiliations

  • Shandong Cancer Hospital Affiliated To Shandong University, Shandong Cancer Hospital Affiliated to Shandong University, 250117 - Jinan/CN
More

Abstract 1241P

Background

Brain metastases (BM) are a frequent and severe complication associated with lung adenocarcinoma patients harboring EGFR mutation, up to 60% of patients in Asia present it. It is unclear whether synchronous or sequential dose addition based on whole brain radiation therapy (WBRT) and local radiotherapy for metastatic disease is superior to WBRT alone for the treatment of advanced EGFR-mutant NSCLC with brain metastases remains controversial.

Methods

We retrospectively evaluated EGFR-mutant lung adenocarcinoma patients with BMs from a single site. Patients were divided into three groups based on upfront therapy: WBRT, local radiotherapy, synchronous or sequential dose addition based on WBRT, and subsequently stratified by Lung-molGPA.

Results

The median OS for the WBRT (n=84), local radiotherapy (n=65), and WBRT+Boost (n=84) cohorts were 32.8, 59.1, and 41.7 months, respectively (P =0.0002). After stratification according to the Lung-molGPA standard, in the group with a score of 1-2, the median OS for the WBRT (n=56), local radiotherapy (n=19), and WBRT+Boost (n=28) cohorts was 32.5, 30.9, and 30.8 months, respectively (P=0.5097). And in the group with a score of 2.5-4, the median OS for the WBRT (n =26), local radiotherapy (n=45), and WBRT+Boost (n=55) cohorts was 32, 68.4, and 51 months, respectively (P=0.0045).

Conclusions

This retrospective analysis showed that craniocerebral radiotherapy should be based on the patient's Lung-molGPA score in patients with EGFR-mutant lung adenocarcinoma with BM. In patients with Lung-molGPA > 2, the OS of patients with local radiotherapy was significantly longer than that of WBRT, but there was no significant difference in the effect of three radiotherapy regimens on OS in patients with Lung-molGPA < 2. Therefore, the craniocerebral radiotherapy plan of patients should be individualized according to Lung-molGPA score.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings